The synthesis and characterization of two new sets of arylsulfonehydrazone benzenesulfonamides (4a-4i with phenyl tail and 4j-4q with tolyl tail) are reported. The compounds were designed according to a dual-tails approach to modulate the interactions of the ligands portions at the outer rim of both hydrophobic and hydrophilic active site halves of human isoforms of carbonic anhydrase (CA, EC 4.2.1.1). The synthesized sulfonamides were evaluated in vitro for their inhibitory activity against the following human (h) isoforms, hCA I, II, IV and IX. With the latter being a validated anticancer drug target and a marker of tumor hypoxia, attractive results arose from the Compounds' inhibitory screening in terms of potency and selectivity. Indeed, whereas the first subset of compounds 4a-4i exhibited great efficacy in inhibiting both the ubiquitous, off-target hCA II (K I s 9.5e172.0 nM) and hCA IX (K I s 7.5e131.5 nM), the second subset of tolyl-bearing derivatives 4j-4q were shown to possess a selective hCA IX inhibitory action over isoforms I, II and IV. The most selective compounds 4l and 4n were further screened for their in vitro cytotoxic activity against MCF-7 and MDA-MB-231 cancer cell lines under hypoxic conditions. The selective IX/II inhibitory trend of 4j-4q compared to those of compounds 4a-4i was unveiled by docking studies. Further exploration of these molecules could be useful for the development of novel antitumor agents with a selective CA inhibitory mechanism.
Introduction
Human carbonic anhydrase (CA, EC 4.2.1.1) IX is a membranebound enzyme whose expression is strongly induced by hypoxia, a condition featured by low level of oxygen occurring in different types of solid tumors, such as glioma, breast cancer and colon carcinoma [1e3] . The activity of the over-expressed hCA IX maintains a proper external pH, supporting an acidic extracellular microenvironment suited for hypoxic tumor cells, thus regulating cell proliferation, adhesion, and malignant cell invasion [1] . hCA IX inhibition has been shown to be associated with a significant suppression of the growth of both primary tumors and metastases, recognizing such an isozyme as a validated anticancer drug target, marker of tumor hypoxia and prognostic factor for several types of cancers [4, 5] . With its expression being limited in normal tissues, hCA IX has become an attractive target for the design of antineoplastic drugs [6] . Despite that acetazolamide (AAZ) and other sulfonamide CAIs were reported to slowdown tumor growth and to delay tumor development, the lack of selectivity of sulfonamidelike CAIs against the different human (h) isozymes is the main issue that prevents a wider pharmaceutical application to date [1, 7, 8] . Typically, the sulfonamide moiety coordinates the Zn ion present within the hCAs active sites and establishes two additional hydrogen bonds with a residue nearby (Thr199). Such binding features are common among the active site architectures of all the 15 human isozymes, 1 which belong to the a-class (seven distinct genetic families have been identified so far, the a-, b-, g-, d-, z-. hand q-CAs) [8, 9] . The active site cavity of hCAs is divided into two very different environments: the first one is delimited by a cluster of hydrophobic amino acids, whereas the other one is lined with hydrophilic residues (Fig. 1) [8, 9] .
Different approaches have been employed to design sulfonamide CAIs that exceed the poor selectivity boundary, with the "tail approach" being the most efficient and exploited one ( Fig. 1 ) [4, 10, 11] . It consists in appending different molecular moieties (tails) to the aromatic/heterocyclic ring bearing the zinc binding group, in order to modulate the interaction with the middle and the rim parts of the active site cavity, which is the most variable region among the 15 isoforms mentioned above. In this context, a ureidotailed sulfonamide CAI (SLC-0111) successfully completed Phase I clinical trials for the treatment of advanced, metastatic hypoxic tumors over-expressing hCA IX, being scheduled for Phase II trials later last year [4, 12] .
In the present work, we apply a dual-tails approach to modulate the interactions of the ligands at the outer rim of both hydrophobic and hydrophilic regions, seeking for isoform-selective inhibition profiles. Dual-tails CAIs were previously reported by Tanpure et al. by applying the "Click approach" to combine glyosidic and phenyl portions onto a sulfonamide scaffold [13] .
The herein designed compounds 4a-q possess a Zinc Binding Group (ZBG) of the benzenesulfonamide type and a highly flexible molecular structure of the methyl hydrazone type to enhance the probability of a proper orientation and contacts with both hydrophilic and hydrophobic halves of the active site. A sulfone group was incorporated to increase the binding to the hydrophilic part of the active site. The aromatic tail appended at the sulfone moiety is of the phenyl or tolyl type as shown in Fig. 1 . On the other hand, the use of diverse hydrophobic substituents on the hydrazine-linked aromatic portion should ensure suited SAR exploration regarding the hydrophobic region. All of these designed compounds were synthesized, characterized and biologically tested against four relevant hCA isoforms (I, II, IV and IX). Furthermore, compounds with best hCA IX inhibition properties have been subjected to cytotoxic activity evaluation against two different cell lines expressing the tumorassociated isozyme.
Results and discussion

Chemistry
To obtain the target compounds 4a-q, variable 2-bromoacetyl aryl or heteroaryl derivatives (2a-k) were refluxed separately with sodium benzene sulfinate in ethanol obtaining different phenyl sulfones 3a-q [14] . Consequently, the intermediate compounds 3a-q were refluxed with 4-hydrazinobenzene sulfonamide HCl salt in ethanol and catalytic amount of acetic acid to afford the hydrazones 4a-q (Scheme 1). 1 H NMR of compounds 4a-q revealed the two protons of the active methylene group (-SO 2 CH 2 -) which appeared as singlet at nearly d ¼ 5.01 ppm. In addition, 13 C NMR confirmed this data by illustrating a peak for this carbon (-SO 2 CH 2 -) at about d ¼ 54.3 ppm. Peaks of D 2 O exchangeable protons were important in this analysis to confirm that the reaction was complete.
1 H NMR analysis of compound 4i was very interesting as it informed us that this compound presented in Z and E isomers by ratio (2:1) when this compound was dissolved in DMSO. Otherwise, all the synthesized compounds were expected to be found in one conformer in solid state, which is Z conformer analogous to the reported compounds [15e17].
Biological evaluation
Carbonic anhydrase inhibition
The CA inhibitory properties of sulfonamide derivatives 4a-4q against human isoforms CA I, II, IV and IX were measured using acetazolamide (AAZ) as standard inhibitor by a stopped flow CO 2 hydrase assay [18] . The rational for the choice of these four isoforms is that the ubiquitous hCA I and II are the main off-target isoforms for the anticancer CAIs therapeutic application. Isoform hCA IV shares with hCA IX the extra-cellular localization and is a drug target for retinitis pigmentosa, stroke and inflammatory pathologies such as rheumatoid arthritis.
The following structure-activity relationship (SAR) were obtained from the inhibition data reported in Table 1: (i) The off-target isoform hCA I was moderately inhibited by sulfonamides 4a-4q herein reported with inhibition constants (K I s) spanning in the high nanomolar-low micromolar range, between 272.1 and 3771.1 nM. Noteworthy, increasing steric hindrance on the hydrazone aromatic portion almost generally worsened the hCA I inhibitory efficacy of the reported series of dual-tails sulfonamides. As a matter of fact, Fig. 1 . Design approach to arylsulfone-based benzenesulfonamides (4a-4q Finally, the methyl-devoid compounds displayed weak selectivity for hCA IX and over hCA II, whereas the SI markedly increased for the methyl-bearing subset, with compounds 4l and 4n possessing an interesting selectivity with SI 38.01 and 63.74, respectively (Table 1) .
In vitro cytotoxic assay
The p-Cl and p-CH 3 -bearing compounds 4l and 4n within the tolyl-derivatives subset were further screened for their in vitro cytotoxic activity, owing to their unique potency and selectivity against the tumor-associated isoform hCA IX. Due to the recognized expression of the latter in breast malignancies [19, 20] , these compounds were screened against human breast adenocarcinoma cell line (MCF-7) and triple negative breast cancer cell line (MDA-MB-231) using doxorubicin as a reference drug. The assay was run under hypoxic conditions of 5% CO 2 at 37 C and the IC 50 values in mM conc. of both compounds relative to doxorubicin is presented in Table 2 . The results of the in vitro screening reported in Table 2 revealed that both compounds generally exhibited better cytotoxic activity against (MCF7) cell line than (MDA-MB-231). Compound 4n, incorporating a dual-tolyl group in both tails, displayed better activity than the p-Cl derivative 4l, with its activity being the half of that displayed by the reference drug doxorubicin.
Molecular docking studies
The binding modes of the herein reported compounds within the CA isozymes II and IX (PDB 5LJT [21] and 5FL4 [22] , respectively; hCA IX residues are reported in brackets), were explored by docking and MM-GBSA simulations to unveil the relationships between structural features and the inhibition profiles. As expected by the in vitro results, in all docking solutions the benzenesulfonamide moiety is oriented deeply into the active sites of both the isoforms engaging two hydrogen bonds with the hCA II Thr199 (hCA IX Thr200). Its negatively charged nitrogen atom directly coordinated the zinc ion and the hydrophobic region lined by Val121, Val143 and Leu198 (hCA IX Val121, Val142 and Leu199) accommodated the phenyl ring. For all 4a-q derivatives, the tail appended at the benzenesulfonamide was similarly oriented in the two isoform active sites (Fig. 2 ). This orientation was primarily determined by the three-center H-bond that the sulfone (SO 2 ) moiety engaged with the HE-Gln92 (HE-Gln92) and HD-Asn67 (HE-Gln71) atoms of the "hydrophilic" region of both active sites. Such a set of interactions strongly affected the positioning of the sulfone-linked aromatic portion of the ligands within the region lined by Ile91 (Leu91), Glu69 (Thr73) and Arg58 (Arg62), while the hydrazone aromatic portions accommodated in a wide hydrophobic area defined by Phe131, Val135, Leu204, Pro202, Pro201 and Leu198 (Val130, Leu 134, Ala205, Pro203, Pro202 and Leu199), with p-p and p-alkyl interactions occurring between the aryl group and lipophilic side chains.
A key role is played by the hCA II/IX Glu69/Thr73 mutation in explaining the trend of inhibition profiles of derivatives 4a-4i and 4j-4q against trans-membrane hCA IX over the cytosolic hCA II (Fig. 3) . Indeed, in hCA IX the para methyl-substituent on the terminal aromatic ring of 4j-4q is oriented towards Thr73, with lipophilic interactions stabilizing the pose. Moreover, the less bulky Thr73 residue in hCA IX provides to the aromatic (un/)substituted tails more space than the Glu69 in the hCA II. As a matter of fact, the Glu69 e Arg58 charge interaction of the cytosolic isoform, constrains the position of the Glu69 and prevents an ideal shape complementarity of the substituted derivatives thus explaining the worst inhibition profile when compared with the unsubstitued ones.
It is reasonable to ascribe the potent and IX/II selective efficacy of compounds 4l, 4n and 4p (II/IX ratio of 38, 64 and 28) within the p-methyl-substituted subset to most favorable interactions taking place between the p-Cl, p-CH 3 and 2-naphthyl moieties, respectively, with the aforementioned lipophilic region of the tumorassociated isoform IX (Fig. 3 ).
Conclusion
In the present study, we reported the synthesis and characterization of two new series of arylsulfonehydrazone benzenesulfonamide (4a-4i and 4j-4q). The compounds were designed according to a dual-tails approach to modulate the interactions of the ligands portions at the outer rim of both hydrophobic and hydrophilic active site halves of varied hCAs. The in vitro evaluation of the newly synthesized sulfonamides against hCA I, II, IV and IX furnished interesting results in terms of compounds inhibitory potency and selectivity. Indeed, whereas the first subset of compounds 4a-4i (unsubstituted phenyl-bearing) exhibited great efficacy in inhibiting both the ubiquitous, off-target hCA II (K I s 9.5e172.0 nM) and hCA IX (K I s 7.5e131.5 nM), the tolyl-bearing derivatives 4j-4q were shown to possess a selective hCA IX inhibitory action over isoforms I, II and IV. In vitro cytotoxic activity evaluation of the most IX/II selective compounds 4l and 4n against MCF-7 and MDA-MB-231 cell lines under hypoxic conditions showed an efficient anti-proliferative action in the low micromolar range, with compound 4n showing a two-fold reduced efficacy than that shown by the reference drug doxorubicin. The study of the derivatives binding mode by modelling studies performed for all compounds with hCA II and IX shed light on the five-to sixty-fold II/IX selective inhibitory efficacy of 4j-4q.
Experimental
Chemistry
General
Melting points were recorded on a Stuart SMP10 digital melting point apparatus and were uncorrected. Infrared (IR) Spectra were recorded as KBr disks using a Shimadzu FT-IR 8400S infrared spectrophotometer. Mass spectral data are given as m/z (Intensity 
General procedure for the preparation of compounds 4a-q
To a solution of the appropriate 1-aryl or heteroaryl-substituted 2-(aryl sulfonyl) ethanone 3a-q (1 mmol) in absolute ethanol in the presence of catalytic amount of glacial acetic acid, 4-hydrazinobenzenesulfonamide (0.187 g, 1 mmol) was added. The reaction mixture was heated under reflux. The solid formed was collected by filtration, dried and recrystallized from ethanol/DMF to afford compounds 4a-q. Phenol red (at a concentration of 0.2 mM) has been used as indicator, working at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.5) as buffer, and 20 mM Na 2 SO 4 (for maintaining constant the ionic strength), following the initial rates of the CAcatalyzed CO 2 hydration reaction for a period of 10e100 s. The CO 2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor at least six traces of the initial 5e10% of the reaction have been used for determining the initial velocity. The un-catalysed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of the inhibitor (0.1 mM)
4-[2-(1-(4-Fluorophenyl)-2-(phenylsulfonyl)ethylidene) hydrazinyl] benzenesulfonamide (4a
were prepared in distilled-deionized water and dilutions up to 0.01 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were pre-incubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. The inhibition constants were obtained by nonlinear least-squares methods using PRISM 3 and the ChengePrusoff equation, as reported earlier [29e32]. and represent the mean from at least three different determinations. All CA isoforms were recombinant ones obtained in-house as reported earlier [33e35].
In vitro cytotoxic assay
MCF-7 and MDA-MB-231 cancer cell lines were obtained from the American wild type collection. Incubation of the cells was done under hypoxic conditions of 5% CO 2 , all other procedures regarding the assay was done using MTT assay as reported [36] .
Computational studies
5LJT (hCA II) [21] and 5FL4 (hCA IX) [22] crystal structures were prepared according to the Protein Preparation module in MaestroSchr€ odinger suite, assigning bond orders, adding hydrogens, deleting water molecules, and optimizing H-bonding networks. Finally, energy minimization with a root mean square deviation (RMSD) value of 0.30 was applied using an Optimized Potentials for Liquid Simulation (OPLS_2005) force field [37] . 3D ligand structures were prepared by Maestro, evaluated for their ionization states at pH 7.4 ± 0.5 with Epik OPLS-2005 force field in Macromodel was used for energy minimization for a maximum number of 2500 conjugate gradient iterations and setting a convergence criterion of 0.05 kcal mol À1 Å
À1
. Grids for docking were centered in the centroid of the complexed ligand. Flexible docking studies were carried out with the program Glide, using the standard precision (SP) mode, turning on the sampling of ring conformation option and the postdocking minimization. The best scored docking poses were selected and passed onto Prime for refinement with the VSGB continuum solvent model [38] .
